Expertise in
13
conditions

Dr. Emily K. Slotkin

Hematology | Oncology
Memorial Sloan Kettering Cancer Center
1275 York Ave, 
New York, NY 
Accepting New Patients
Expertise in
13
conditions
Memorial Sloan Kettering Cancer Center
1275 York Ave, 
New York, NY 

Overview

Emily Slotkin is a Hematologist and an Oncologist practicing medicine in New York, New York.

Dr. Slotkin is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Desmoplastic Small Round Cell Tumor, Adult Soft Tissue Sarcoma, Bone Tumor, and Osteosarcoma.

She is actively involved in clinical research, co-authoring 52 peer reviewed articles and participating in 5 clinical trials. Dr. Slotkin is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatrics in NY

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Memorial Sloan Kettering Cancer Center
1275 York Ave, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Enrollment Status: Completed
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Ramucirumab, Cyclophosphamide, Vinorelbine
Study Phase: Phase 1/Phase 2
A Phase I/II Dose Escalation/Dose Expansion Study of Prexasertib in Combination With Irinotecan in Patients With Relapsed or RefractoryDesmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
A Phase I/II Dose Escalation/Dose Expansion Study of Prexasertib in Combination With Irinotecan in Patients With Relapsed or RefractoryDesmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
Enrollment Status: Completed
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: Prexasertib, Irinotecan
Study Phase: Phase 1/Phase 2
Phase I Trial of Pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex (LPX) in Subjects With Advanced Ewing's Sarcoma
Phase I Trial of Pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex (LPX) in Subjects With Advanced Ewing's Sarcoma
Enrollment Status: Completed
Publish Date: November 13, 2023
Intervention Type: Biological
Study Drug: pbi-shRNA™ EWS/FLI1 Type 1 LPX
Study Phase: Phase 1
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Enrollment Status: Terminated
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: May 20, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

52 Total Publications

Does Longitudinal Targeted Panel Sequencing Provide Clinically Relevant Information in Translocation-Associated Sarcomas?
Does Longitudinal Targeted Panel Sequencing Provide Clinically Relevant Information in Translocation-Associated Sarcomas?
Journal: JCO precision oncology
Published: April 23, 2026
Similar Doctors
Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.3 miles away)
646-535-8986
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Horwitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Horwitz is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Horwitz is currently accepting new patients.

Expertise in
27
conditions
Dr. Gilles A. Salles
Hematology | Oncology
Expertise in
27
conditions
Dr. Gilles A. Salles
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.3 miles away)
929-298-9410
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gilles Salles is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Salles is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Bone Marrow Transplant, and Splenectomy. Dr. Salles is currently accepting new patients.

Expertise in
31
conditions
Dr. Alison J. Moskowitz
Hematology | Oncology
Expertise in
31
conditions
Dr. Alison J. Moskowitz
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.3 miles away)
332-456-0508
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alison Moskowitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Moskowitz is highly rated in 31 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Moskowitz is currently accepting new patients.

Frequently Asked Questions about Dr. Emily K. Slotkin

How do I make an appointment with Dr. Emily K. Slotkin?

You can book an appointment with Dr. Emily K. Slotkin by calling their office at 315-275-7390. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Emily K. Slotkin a top-rated expert for Desmoplastic Small Round Cell Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Emily K. Slotkin is classified as an Elite expert for Desmoplastic Small Round Cell Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Emily K. Slotkin specialize in?

While Dr. Emily K. Slotkin is a Hematology, they have specific expertise in Desmoplastic Small Round Cell Tumor, Adult Soft Tissue Sarcoma, and Bone Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Emily K. Slotkin participate in research or clinical trials?

Yes. Dr. Emily K. Slotkin has published 52 articles and abstracts on conditions like Desmoplastic Small Round Cell Tumor. You can view a list of Dr. Emily K. Slotkin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Emily K. Slotkin accept my insurance?

Dr. Emily K. Slotkin accepts most major insurance plans, including Cigna and Horizon Healthcare. We recommend calling the office directly at 315-275-7390 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Slotkin's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile